[Biopharmaceutical Company Moderna to Join Nasdaq 100 Today, High-Profit Accounts Expect a 70% Stock Price Increase] BlockBeats News, October 9 – On October 9, Moderna will officially be included in the Nasdaq 100 Index before the U.S. stock market opens at 9:30 PM Beijing time (October 9), replacing Warner Bros. Discovery. This adjustment was announced on October 1. From the close of the U.S. stock market on October 1, prior to the announcement, to the latest close on October 8, MRNA's stock price rose from $188.94 to $197, an increase of approximately 4.27%. Moderna is a U.S.-based biotechnology company that develops vaccines and drugs using mRNA technology, with research spanning infectious diseases, cancer, and rare diseases. Beyond its vaccine business, the company announced positive Phase 3 trial results in August for its personalized mRNA cancer therapy developed in collaboration with Merck, achieving the primary endpoint of recurrence-free survival in adjuvant treatment for melanoma, which served as a major catalyst for its stock price. Recently, reports of a suspected pneumonic plague incident in Russia have also drawn attention to vaccine stocks. On October 5, Moderna's stock rose approximately 6.95%. However, as of the latest public information, the pathogen of the incident has not been confirmed by the WHO, and Russian authorities stated that tests on contacts did not detect plague. The European Centre for Disease Prevention and Control also noted that there is no evidence of sustained human-to-human transmission. According to TradingBeats monitoring, MRNA on-chain contracts were priced at $196.45, up approximately 0.56% in 24 hours. The open interest was about 15,600 contracts, with a notional value of approximately $3.059 million. Around 43,500 contracts were traded in 24 hours, with a trading volume of approximately $8.521 million. The two largest long positions collectively hold approximately $448,500 in long positions, with unrealized gains of about $61,500: - Largest long position: Approximately $242,500 in long positions. Held 1,233.05 contracts with 3x leverage at an average price of $175.78, with unrealized gains of about $25,800 and a return of approximately 35.7%. Liquidation price: $124.15 (0x9a37…). - Second-largest long position: Approximately $205,900 in long positions. Held 1,046.98 contracts with 10x leverage at an average price of $162.58, with unrealized gains of about $35,700 and a return of approximately 209.8%. Liquidation price: $154.69 (0x599d…). The second-largest long position has set a market take-profit trigger order at $350 to cover all existing positions, approximately 77.9% higher than the current price.